Dizziness, somnolence, and mental status changes have occurred in patients taking difelikefalin. Difelikefalin may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Advise patients not to drive or operate dangerous machinery until the effect of difelikefalin on a patient’s ability to drive or operate machinery is known.
- TRADE NAME: Korsuva (Cara Therapeutics)
- INDICATIONS:
Treatment of pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
- CLASS: Opioid agonist, Opioid kappa receptor agonist
- HALF-LIFE: 23–31 hours (in hemodialysis patients prior to dialysis)
- FDA APPROVAL DATE: 08/23/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
No clinical studies evaluating the drug interaction potential of difelikefalin were conducted. - PREGNANCY: Insufficient data in pregnant women to evaluate a drug-associated risk for major birth defects or miscarriage.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
